Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:
“Lu-Edotreotide improves PFS compared to everolimus in both treatment naive and pretreated patients in grade1-2 NET. OS results immature: Compete phase 3 trial.”
